GlassScriptPhysician profile
Stephen S Matter
NPI 1134228224
$15,572.30
in general payments reported to CMS, 2019-2025
40 companies · $3,302 in 2025
The $3,302 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,807 · 2020: $1,355 · 2021: $1,919 · 2022: $2,202 · 2023: $2,231 · 2024: $2,756 · 2025: $3,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,053 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,052.88 |
| Education | $236.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,343.36 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,262.64 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,685.13 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,615.56 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $528.74 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $426.52 | 2024-2025 | Zenpep, Vowst |
| Braintree Laboratories, INC. | $388.27 | 2019-2025 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $373.44 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $326.11 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $286.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Mauna Kea Technologies, INC. | $280.86 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $240.47 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $234.35 | 2019-2024 | Dificid, Zinplava |
| Daiichi Sankyo INC. | $223.05 | 2019-2025 | Injectafer |
| Pfizer INC. | $214.01 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $200.02 | 2019-2020 | |
| Lilly USA, LLC | $196.53 | 2025 | Omvoh, Zepbound |
| Gilead Sciences, INC. | $186.89 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $177.75 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $165.45 | 2019-2024 | Rebyota |
| Ardelyx, INC. | $117.44 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $111.99 | 2025 | |
| Concordia Pharmaceuticals INC. | $111.64 | 2019 | |
| Organon LLC | $107.26 | 2022-2024 | |
| Qol Medical, LLC | $99.96 | 2022-2024 | Sucraid, Sucraid |
| Celltrion USA INC. | $96.33 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Intercept Pharmaceuticals, INC. | $78.24 | 2019-2020 | |
| Amgen INC. | $77.62 | 2022-2023 | Amjevita, Avsola |
| Redhill Biopharma INC. | $69.51 | 2020 | |
| Vivus LLC | $51.48 | 2021-2025 | Pancreaze |
| Shionogi INC | $48.50 | 2019-2020 | |
| Novo Nordisk INC | $45.84 | 2023-2025 | Wegovy |
| Fresenius Kabi USA, LLC | $35.05 | 2023 | Idacio |
| Alfasigma USA, INC. | $31.83 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.86 | 2023-2024 | Cyltezo |
| Sandoz INC. | $28.13 | 2023-2024 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $28.13 | 2025 | Iqirvo |
| Csl Behring | $20.00 | 2019 | |
| Allergan, INC. | $16.61 | 2019 | |
| Digestive Care, INC. | $10.34 | 2023 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Matter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.